Patterns and timing of recurrence following CRS and HIPEC in colorectal cancer peritoneal metastasis
Soh, Yen Jia
Wilson, Malcolm S
O'Dwyer, Sarah T
AffiliationThe Christie Peritoneal and Oncology Centre, Manchester, M20 4 BX, United Kingdom.
MetadataShow full item record
AbstractIntroduction: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) is an established treatment of Colorectal Peritoneal Metastases (CRPM). This study aims to determine the timing and patterns of recurrent disease on imaging following complete CRS/HIPEC. Methods: Retrospective analysis of a national peritoneal tumour service database identified CRPM patients with complete CRS/HIPEC(CC0) from 2005 to-2018. Patients with<2 years follow-up or and those where post-operative histology from the CRS/HIPEC procedure did not confirm CRPM from their original colorectal cancer were excluded. Time to recurrence was measured from surgery to first radiologically illustrated recurrence. CT was the primary modality used, supplemented by PET-CT or MRI if required. Outcomes of interest were survival data (including overall survival (OS), disease-free survival (DFS) and peritoneal-recurrence free survival (PRFS)), timing and patterns of recurrent disease. Results: 146 of the 176 patients identified were eligible for inclusion. Median OS for all study patients was 45.2 months (95% CI 38-53 months), median DFS was 11.7 months (95% CI 9-14 months), and median PRFS was 25.2 months (95% CI 14.7-30 months). Recurrent disease was seen in 112 cases (77%), radiologically classified as intraperitoneal in 50 patients (44%), single site systemic in 21 patients (19%) and multi-site in 41 patients (37%). CT detection rate for disease recurrence was 88%. Subgroup analyses showed that PCI ≥12, positive nodal primary disease and synchronous peritoneal disease were associated with worse outcomes. Conclusion: Patients selected for CRS/HIPEC for CRPM have an OS > 45 months, with the majority recurring systemically within a year. Peritoneal recurrence is a later event after several years. Surveillance programs in this group should be most intensive in the first 2 years after surgery, using CT with oral and intravenous contrast.
CitationHassan S, Malcomson L, Soh YJ, Wilson MS, Clouston H, O'Dwyer ST, et al. Patterns and Timing of Recurrence following CRS and HIPEC in Colorectal Cancer Peritoneal Metastasis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2022 Aug 4. PubMed PMID: 35987797. Epub 2022/08/21. eng.
JournalEuropean Journal of Surgical Oncology
- Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
- Authors: Pantelis A, Ben-Yaacov A, Adileh M, Schtrechman G, Shacham-Shmueli E, Boursi B, Margalit O, Halpern N, Mor E, Assaf D, Maximiliano K, Nissan A, Laks S
- Issue date: 2022 Aug
- [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
- Authors: Yu Y, Li XB, Lin YL, Ma R, Ji ZH, Zhang YB, An SL, Liu G, Yang XJ, Li Y
- Issue date: 2021 Mar 25
- Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry.
- Authors: Kelly ME, O'Sullivan NJ, Bolger JC, Polignano F, Youssef H, Renehan A, Malcomson L, Alves S, Cecil T, Mulsow J, Moran B, Mohamed F, UK & Ireland Colorectal Peritoneal Metastases Registry
- Issue date: 2023 Jan
- Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
- Authors: Feferman Y, Solomon D, Bhagwandin S, Kim J, Aycart SN, Feingold D, Sarpel U, Labow DM
- Issue date: 2019 Feb
- RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
- Authors: Bhullar D, O'Dwyer S, Wilson M, Saunders MP, Kochhar R, Barriuso J, Aziz O
- Issue date: 2023 Feb